@article{8913cbae3a9c43c493fabe761f46f965,
title = "Improving the Affordability of Anticancer Medicines Demands Evidence-Based Policy Solutions",
abstract = "The high cost of many new anticancer medicines significantly impedes breakthrough discoveries from reaching patients. A commonly heard refrain is that high prices are necessary to compensate for the high costs of research and development (R&D). Yet, there are promising policy proposals aimed at improving affordability without compromising innovation. In seeking new policy solutions, we argue for a shift away from entrenched opinion toward an evidence-based discourse that is grounded in experiments and real-world pilot studies. We offer a novel perspective and practical recommendations on how empirical evidence could and should be gath-ered to inform evidence-based policy interventions that lead to sustainable medicine prices in oncology.",
keywords = "n/a OA procedure",
author = "Nora Franzen and Giorgia Romagnoli and Andreas Ziegler and Ret{\`e}l, {Valesca P.} and Offerman, {Theo J.S.} and {van Harten}, {Wim H.}",
note = "Funding Information: N. Franzen reports grants from a philanthropist (unrestricted) during the conduct of the study. G. Romagnoli reports having recently coauthored a paper on incentivizing mindfulness meditation practices for better mental health. This project, completely outside of the scope of the project under publication, was funded by a Dutch insurance company, Zilveren Kruis Zorgverzekeringen N.V., based on a research partnership between Zilveren Kruis and G. Romagnoli{\textquoteright}s coauthors on the project at Duke University (the funding was used to hire a research assistant and pay the experimental subjects). G. Romagnoli did not receive financial compensation for this work, and G. Romagnoli{\textquoteright}s relationship with Zilveren Kruis has since concluded. V.P. Ret{\`e}l reports grants from a philanthropist (unrestricted) during the conduct of the study, as well as grants from Intuitive B.V. outside the submitted work. W.H. van Harten reports grants from a private sponsorship during the conduct of the study; grants from Organisation of European Cancer Institutes outside the submitted work; and is Chair, Working Group Health Economics, OECI, and CEO Rijnstate General Hospital, Arnhem, the Netherlands. No disclosures were reported by the other authors. Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research.",
year = "2022",
month = feb,
day = "1",
doi = "10.1158/2159-8290.CD-21-1153",
language = "English",
volume = "12",
pages = "299--302",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "2",
}